Modern molecular diagnostics and the management of haematological malignancies

被引:16
|
作者
Morgan, GJ [1 ]
Pratt, G [1 ]
机构
[1] Univ Leeds, Gen Infirm, Dept Haematol, Leeds LS1 3EX, W Yorkshire, England
来源
CLINICAL AND LABORATORY HAEMATOLOGY | 1998年 / 20卷 / 03期
关键词
haematological malignancies; immunophenotyping; PCR; FISH; minimal residual disease;
D O I
10.1046/j.1365-2257.1998.00141.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The advent of molecular biological techniques has led to a radical improvement in the evaluation of haematological disorders and offers exciting future prospects. In particular it has led to the improved recognition of distinct clinicopathological entities defined by a combination of morphological, immunophenotypic and chromosomal features. Antibody-based techniques, namely immunophenotyping and immunocytochemical techniques, are essential to malignant haematological diagnosis. More novel is the diagnostic use of antibodies against novel fusion proteins, for example in AML, M3 and anaplastic lymphoma. PCR-based techniques allow the identification of genetic mutations and translocations including such common translocations as t(14;18), t(9:22), inv 16 and t(8;21). Fish-based techniques are greatly improving the ability to detect genetic abnormalities including those conditions with low cell proliferation and current research-based techniques include the combination of FISH with cell surface markers (FICTION), FIBRE FISH and Comparative Genomic Hybridization. Molecular techniques are essential in monitoring residual disease which is best illustrated in CML, The development of real-time automated PCR offers exciting prospects in this field, The increasing number of tests, the need for an integrated approach to diagnosis and the need for cost effectiveness indicate that such services should be provided by a specialized haematology laboratory.
引用
收藏
页码:135 / 141
页数:7
相关论文
共 50 条
  • [41] Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies
    Crassini, Kyle
    Gibson, John
    INTERNAL MEDICINE JOURNAL, 2024, 54 (01) : 16 - 25
  • [42] Molecular diagnostics and NSCLC management
    不详
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 1 - 1
  • [43] Molecular diagnostics in the management of rhabdomyosarcoma
    Arnold, Michael A.
    Barr, Fredric G.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2017, 17 (02) : 189 - 194
  • [44] Cellular therapy for haematological malignancies
    Roddie, PH
    Turner, ML
    VOX SANGUINIS, 2002, 83 (04) : 294 - 304
  • [45] BONE MANIFESTATIONS OF HAEMATOLOGICAL MALIGNANCIES
    Mzabi, Anis
    Fakhfakh, Rym
    Ben Hassine, Imen
    Anoun, Jihed
    Karmani, Monia
    Ben Fredj, Fatma
    Laouani, Chadia
    RHEUMATOLOGY, 2021, 60 : V24 - V24
  • [46] Bispecific antibodies in haematological malignancies
    Viardot, Andreas
    Bargou, Ralf
    CANCER TREATMENT REVIEWS, 2018, 65 : 87 - 95
  • [47] Targeting Hedgehog in haematological malignancies
    Ghia, Paolo
    LANCET HAEMATOLOGY, 2015, 2 (08): : E311 - E312
  • [48] Clozapine and the risk of haematological malignancies
    Schulte, Peter F. J.
    Cohen, Dan
    Veerman, Selene R. T.
    Bakker, Bert
    Bogers, Jan P. A. M.
    LANCET PSYCHIATRY, 2022, 9 (07): : 538 - 539
  • [49] Cellular immunotherapy in haematological malignancies
    Reid, CDL
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 7 - 10
  • [50] Immunomodulation in the treatment of haematological malignancies
    Cesco-Gaspere, Michela
    Morris, Emma
    Stauss, Hans J.
    CLINICAL AND EXPERIMENTAL MEDICINE, 2009, 9 (02) : 81 - 92